Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 32919526

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Oct
First author
Marabelle A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Oct;21(10):1255-1257. doi: 10.1016/S1470-2045(20)30433-2.
    note
    Source null
    related pmid
    32919529
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2020 Dec;17(12):718. doi: 10.1038/s41571-020-00438-0.
    note
    Source null
    related pmid
    32968242
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2020 Dec;21(12):e551. doi: 10.1016/S1470-2045(20)30617-3.
    note
    Source null
    related pmid
    33271108
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2020 Dec;21(12):e552. doi: 10.1016/S1470-2045(20)30697-5.
    note
    Source null
    related pmid
    33271109
    relationship
    Comment in

Authors and identifiers

  1. name
    Marabelle A
    type
    Author
  2. name
    Fakih M
    type
    Author
  3. name
    Lopez J
    type
    Author
  4. name
    Shah M
    type
    Author
  5. name
    Shapira-Frommer R
    type
    Author
  6. name
    Nakagawa K
    type
    Author
  7. name
    Chung HC
    type
    Author
  8. name
    Kindler HL
    type
    Author
  9. name
    Lopez-Martin JA
    type
    Author
  10. name
    Miller WH Jr
    type
    Author
  11. name
    Italiano A
    type
    Author
  12. name
    Kao S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Marabelle A
    type
    Author
  2. name
    Fakih M
    type
    Author
  3. name
    Lopez J
    type
    Author
  4. name
    Shah M
    type
    Author
  5. name
    Shapira-Frommer R
    type
    Author
  6. name
    Nakagawa K
    type
    Author
  7. name
    Chung HC
    type
    Author
  8. name
    Kindler HL
    type
    Author
  9. name
    Lopez-Martin JA
    type
    Author
  10. name
    Miller WH Jr
    type
    Author
  11. name
    Italiano A
    type
    Author
  12. name
    Kao S
    type
    Author
bibliography ids
  1. nci-bib-1a82279d0bc1679021f730c2
book metadata
content sha256
c261dacf2f5e606fbfaf8855968749cee24de030cfab55fdf7a6d6e6073766b9
document type
citation
dois
  1. 10.1016/S1470-2045(20)30445-9
electronic publication date
display
2020 Sep 10
precision
day
year
2020
evidence scope
bibliographic_metadata_only
id
pubmed:32919526
immutable id
pubmed:32919526@c261dacf2f5e606fbfaf8855968749cee24de030cfab55fdf7a6d6e6073766b9
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
10
name
The Lancet. Oncology
nlm unique id
100957246
pages
1353-1365
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Oct;21(10):1255-1257. doi: 10.1016/S1470-2045(20)30433-2.
    note
    Source null
    related pmid
    32919529
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2020 Dec;17(12):718. doi: 10.1038/s41571-020-00438-0.
    note
    Source null
    related pmid
    32968242
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2020 Dec;21(12):e551. doi: 10.1016/S1470-2045(20)30617-3.
    note
    Source null
    related pmid
    33271108
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2020 Dec;21(12):e552. doi: 10.1016/S1470-2045(20)30697-5.
    note
    Source null
    related pmid
    33271109
    relationship
    Comment in
outcomes validated
false
pmid
32919526
provenance
batch id
9bca82d1bba2b27adc79
provider
NCBI PubMed ESummary
record sha256
5ae249a292b43768d21443be29708fb1f9f5fe16e996a8c354a976c631eab5f7
response sha256
c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
retrieved at
2026-09-09T23:47:56.131551+00:00
publication date
display
2020 Oct
precision
month
year
2020
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32919526/
title
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

Preserved source evidence · Independent clinical review pending · Not medical advice